Cargando…
Fulminant Type 1 Diabetes Mellitus after SARS-CoV-2 Vaccination: A Case Report
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been used worldwide to control the coronavirus disease pandemic. However, several adverse effects have been reported following vaccination. Therefore, further research on the adverse effects in individuals predisposed to life...
Autores principales: | Lin, Rong, Lin, Yu-Wei, Chen, Mei-Hsiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692754/ https://www.ncbi.nlm.nih.gov/pubmed/36423001 http://dx.doi.org/10.3390/vaccines10111905 |
Ejemplares similares
-
New-Onset Fulminant Type 1 Diabetes After SARS-CoV-2 Infection
por: Pan, Yunfei, et al.
Publicado: (2023) -
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech: Fulminant type 1 diabetes mellitus: case report
Publicado: (2022) -
SARS-CoV-2 Fulminant Myocarditis
por: Garot, Jérôme, et al.
Publicado: (2020) -
Diabetic ketoacidosis after the second dose of SARS-CoV-2 mRNA vaccination in a patient with pembrolizumab-induced fulminant type 1 diabetes
por: Nishino, Kohei, et al.
Publicado: (2022) -
Fulminant myocarditis as an early presentation of SARS-CoV-2
por: Naneishvili, Tamara, et al.
Publicado: (2020)